From Hydrochloroquine to Dexamethasone, a number of medicines have been proposed as a COVID 19 treatment, but none has proved to be effective as per the expectations. Why India has dropped the Remdesivir and other medicines that are suggested for trials?
“Remdesivir is showing reports of liver damage in patients from across India. There is multiple evidence that patients who have been given the drug showed a rise in levels of alkaline phosphatase etc that can lead to liver injury,” said a senior health official.
Also under review are Hydroxychloroquine and Lopinavir/Ritonavir, for which the World Health Organisation (WHO) has discontinued solidarity trial for COVID 19. The solidarity trial was established by the WHO to find an effective COVID 19 treatment for hospitalized patients.
This comes days after a government hospital in the capital of India stopped the use of another anti-viral drug Favipiravir (used in mild/moderate cases) because of the complaints, including decreased appetite, nausea, diarrhea, increased uric acid levels, decreased counts of white blood cells and increased liver enzymes levels. Favipiravir is a Japanese company Fujifilm’s flu drug that the company has sent to 43 countries for the COVID 19 trial.
So it can easily be concluded that there is no effective COVID 19 treatment so far, but the research is underway. WHO has brought global health experts and world scientists together to speed up the research and development process. Therefore, the WHO called for solidarity of all the countries, so that they all have access to the COVID related health products.
Follow Gofrixty for more updates.